Immunome Research

Immunome Research
Open Access

ISSN: 1745-7580

+44-77-2385-9429

Mini Review - (2015) Volume 11, Issue 1

Rationale for Bone Marrow Transplantation in Treatment of Various Intractable Diseases

Susumu Ikehara*
Department of Stem Cell Disorders, Kansai Medical University, Hirakata City, Osaka, Japan
*Corresponding Author: Susumu Ikehara, M.D., Ph.D., Department of Stem Cell Disorders, Kansai Medical University, Hirakata City, Osaka 570-1010, Japan, Tel: 81-72-804-2450, Fax: 81-72-804-2454 Email:

Abstract

In this article, we provide evidence that bone marrow transplantation (BMT) can be used to treat various
otherwise intractable diseases. We also show which currently incurable diseases could be treated using our novel BMT methods.

<

Keywords: Autoimmune diseases; Type 1 Diabetes mellitus; Bone marrow; Bone marrow cells; Bone marrow transplantation; Stem cell disorder; Hemopoietic stem cell; Mesenchymal stem cell; Primitive stem cell; Aspiration method; Perfusion method; Intra-bone marrow

Introduction

As long ago as 1985, we discovered, using animal models for autoimmune diseases, that conventional allogeneic BMT could be used to prevent and also treat not only systemic but also organ-specific autoimmune diseases (AIDs).

Our research at that time showed that conventional allogeneic BMT could be used to prevent not only TIDM in NOD mice [1] but also lupus nephritis in lupus mice [2]. In contrast, when BMT was carried out from autoimmune-prone mice to normal mice, the chimeras showed AIDs, strongly suggesting that AIDs were derived from BM defects, since thymus grafts from autoimmune-prone mice to athymic (nu/nu) mice did not result in the development of AIDs [3]. Based on these findings, we focused our research on the BM and eventually discovered a number of BM defects [4-7].

We developed a BMT technique that combines a “PM” for collecting BMCs with the intra-bone marrow (IBM) injection of BMCs (IBM-BMT) [8] (Figure1). As distinct from the conventional AM, the PM allows rapid (within 1 h) collection of BMCs without T cell contamination (T cells<10%). Therefore, no GvHD occurs. Moreover, the burden on donors, such as back pain, bleeding and infection, can be reduced.

immunome-research-BMT-method-allogeneic

Figure 1: A new BMT method for allogeneic BMT. The new method consists of PM+IBM-BMT.

Full chimerism can be achieved even with only mild conditioning regimens if IBM-BMT is carried out, since IBM-BMT replaces not only the recipient’s HSCs but also MSCs with donor-derived HSCs and MSCs. The findings to date strongly suggest that all the body’s cells originate in the BM, and that all diseases might therefore originate from defects in the BM. Indeed, one paper already suggests that gastric cancer originates from BM-derived cells [9].

Finally, I would like to propose a new concept of SCDs (Figure 2). On the one hand, there are HSC disorders, which include (i) aplasia of HSCs (aplastic anemia), (ii) monoclonal or oligoclonal abnormal HSC proliferative syndromes (leukemias and myelodysplastic syndrome), and (iii) polyclonal abnormal HSC proliferative syndromes (autoimmune diseases) [10,11].

immunome-research-novel-concept-stem-disorders

Figure 2: A novel concept of stem cell disorders.

On the other hand, there are MSC disorders, which include age associated diseases such as osteoporosis [12] and emphysema [13], Alzheimer’s disease, and atherosclerosis [8,14]; it has been proposed that autoimmune mechanisms are involved in the development of atherosclerosis [15,16] and also Alzheimer’s disease [17].

Conclusion

We firmly believe that the development of our BMT method heralds a revolution not only in the field of transplantation (BMT and organ transplantation) but also in the fields of cancer and regeneration.

Acknowledgmentss

We would like to thank Mr. Hilary Eastwick-Field and Ms. Keiko Ando for their help in the preparation of the manuscript. These studies were mainly supported by the 21st Century Center of Excellence (COE) program of the Ministry of Education, Culture, Sports, Science and Technology. The Research on Allergic Disease and Immunology Committee from Health and Labour Sciences Research Grants of the Ministry of Health, Labour and Welfare. This study was supported by Otsuka Pharmaceutical Company, Ltd.

References

  1. Ikehara S, Ohtsuki H, Good RA, Asamoto H, Nakamura T, et al. (1985)Prevention of type I diabetes in nonobesediabetic mice by allogenic bonemarrow transplantation. Proc Natl Acad Sci U S A 82: 7743-7747.
  2. Ikehara S, Yasumizu R, Inaba M, Izui S, Hayakawa K, et al. (1989) Longtermobservations of autoimmune-prone micetreated for autoimmunedisease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 86: 3306-3310.
  3. Ikehara S, Tanaka H, Nakamura T, Furukawa F, Inoue S, et al. (1985) Theinfluence of thymic abnormalities on the development of autoimmunediseases. Thymus 7: 25-36.
  4. Ikehara S (2008) A novel method of bone marrow transplantation (BMT)for intractable autoimmune diseases. JAutoimmun 30: 108-115.
  5. Burt RK, Testori A, Craig R, Cohen B, Suffit R, et al. (2008)Hematopoietic stem cell transplantation for autoimmune diseases: whathave we learned? J Autoimmun 30: 116-120.
  6. Marmont AM (2008) Will hematopoietic stem cell transplantation curehuman autoimmune diseases? J Autoimmun 30: 145-150.
  7. Deane S, Meyers FJ, Gershwin ME (2008) On reversing the persistence ofmemory: hematopoietic stem cell transplant for autoimmune disease inthe first ten years. J Autoimmun 30: 180-196.
  8. Kushida T, Inaba M, Ikebukuro K, Ngahama T, Oyaizu H, et al. (2000) Anew method for bone marrow cell harvesting. Stem Cells 18: 453-456.
  9. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, et al. (2004)Gastric cancer originating from bone marrow-derived cells. Science 306:1568-1571.
  10. Bona CA (2002) Autoimmune diseases as stem cell disorders: treatmentby allogeneic bone marrow transplantation. In: Theofilopoulos AN, BonaCA (eds.) Molecular pathology of autoimmune disease. Taylor & Francis,pp. 566-572.
  11. Ikehara S (2003) A new concept of stem cell disorders and their newtherapy. J Hematother Stem Cell Res 12: 643-653.
  12. Ueda Y, Inaba M, Takada K, Fukui J, Sakaguchi Y, et al. (2007) Inductionof senile osteoporosis in normal mice by intra-bone marrow-bonemarrow transplantation from osteoporosis-prone mice. Stem Cells 25:1356-1363.
  13. Adachi Y, Oyaizu H, Taketani S, Minamino K, Yamaguchi K, et al. (2006)Treatment and transfer of emphysema by a new bone marrowtransplantation method from normal mice to Tsk mice and vice versa.Stem Cells 24: 2071-2077.
  14. Ikehara S (2005) Intra-bone marrow-bone marrow transplantation: anew strategy for treatment of stem cell disorders. Ann N Y Acad Sci 1051:626-634.
  15. Fernandes G, Alonso DR, Tanaka T, Thaler HT, Yunis EJ, et al. (1983)Influence of diet on vascular lesions inautoimmune-prone B/W mice.Proc Natl Acad Sci U S A 80: 874-877.
  16. Rose N, Afanasyeva M (2003) Autoimmunity: busting the atheroscleroticplaque. Nat Med 9: 641-642
  17. Baron R, Harpaz I, Nemirovsky A, Cohen H, Monsonego A (2007)Immunity and neuronal repair in the progression of Alzheimer's disease:a brief overview. Exp Gerontol 42: 64-69.
Citation: Ikehara S (2015) Rationale for Bone Marrow Transplantation in Treatment of Various Intractable Diseases. Immunome Res 11:091.

Copyright: © 2015 Ikehara S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top